Complete Genomics (GNOM) versus Medical Transcription Billing (MTBC) Head-To-Head Review

Medical Transcription Billing (NASDAQ: MTBC) and Complete Genomics (NASDAQ:GNOM) are both small-cap computer and technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Medical Transcription Billing and Complete Genomics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medical Transcription Billing 0 0 1 0 3.00
Complete Genomics 0 0 0 0 N/A

Medical Transcription Billing presently has a consensus price target of $2.75, suggesting a potential downside of 7.09%. Given Medical Transcription Billing’s higher probable upside, analysts plainly believe Medical Transcription Billing is more favorable than Complete Genomics.

Valuation and Earnings

This table compares Medical Transcription Billing and Complete Genomics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Medical Transcription Billing $24.49 million 1.39 -$8.79 million ($1.05) -2.82
Complete Genomics N/A N/A N/A ($2.35) -1.34

Complete Genomics has lower revenue, but higher earnings than Medical Transcription Billing. Medical Transcription Billing is trading at a lower price-to-earnings ratio than Complete Genomics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

2.3% of Medical Transcription Billing shares are owned by institutional investors. 53.7% of Medical Transcription Billing shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Medical Transcription Billing and Complete Genomics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Medical Transcription Billing -29.08% -40.41% -15.27%
Complete Genomics N/A N/A N/A

Summary

Medical Transcription Billing beats Complete Genomics on 6 of the 9 factors compared between the two stocks.

Medical Transcription Billing Company Profile

Medical Transcription Billing, Corp. is a healthcare information technology company that provides an integrated suite of Web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. The Company’s offering, PracticePro, allows healthcare practices with the core software and business services on Software-as-a-Service (SaaS) platform. PracticePro includes practice management software and related tools, which facilitate the day-to-day operation of a medical practice; electronic health records (EHR), which allow its customers to qualify for government incentives; revenue cycle management (RCM) services, which include medical billing, analytics and related services, and mobile Health (mHealth) solutions, including smartphone applications that assist patients and healthcare providers in the provision of healthcare services. The Company offers a clearinghouse service, which allows clients to track claim status.

Complete Genomics Company Profile

Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center. Its customers include some of the global academic and government research centers and biopharmaceutical companies. Effective March 18, 2013, BGI-Shenzhen announced that through its wholly-owned subsidiary, Beta Acquisition Corporation, it has completed the acquisition of the Company.

Receive News & Ratings for Medical Transcription Billing Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medical Transcription Billing Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply